Close Menu
    Quds SunQuds Sun
    • Automotive
    • Business
    • Entertainment
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Quds SunQuds Sun
    Home » The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.
    PR Newswire

    The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

    May 18, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    CHENGDU, China, May 18, 2023 /PRNewswire/ — On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center, Sichuan University against the most recent circulating XBB variants, received the “Drug Clinical Trial Approval” from the National Medical Products Administration of China. These two new vaccines will be quickly commercialized for protecting against the current circulating XBB variant when the necessary clinical trials are completed. These two vaccines are also the first COVID-19 vaccines in the world to begin clinical trials specifically for variants like XBB.

    The State Council’s Joint Prevention and Control Mechanism conducted a news conference in early May 2023. The meeting noticed that as inbound and outbound interaction between China and other countries increased, the worldwide impact on the makeup of the key pandemic variants of the novel coronavirus in my country grew dramatically. According to surveillance data[1], the primary pandemic variants of COVID-19 virus in China have evolved into XBB series.  In this context, WestVac Biopharma uses the international advanced insect cell recombinant protein vaccine platform to develop the recombinant bivalent COVID-19 (XBB + prototype strain) protein vaccine (Sf9 cell) Coviccine ® bivalent and recombinant trivalent COVID-19 (XBB + BA.5 + Delta variant) trimeric protein vaccine (Sf9 cell). The two WestVac’s vaccines are crucial for the prevention of the current XBB variants and contribute significantly to the ongoing management of the COVID-19 epidemic.

    Coviccine® Bivalent– Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell)

    The Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) is an upgraded version of Coviccine® –Recombinant COVID-19 Vaccine (Sf9 cell) developed by WestVac Biopharma. Studies have shown that the vaccine induced high titers of neutralizing antibodies against multiple subvariants, including XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1[1], indicating that the vaccine is a universal COVID-19 vaccine effective against multiple strains, especially with a particularly significant increase in neutralizing antibodies against XBB series variants.

    Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Trimeric Protein Vaccine (Sf9 Cell)

    Taking advantage of the rapid response of the internationally advanced insect cell expression platform in recombinant protein vaccine production, WestVac Biopharma and its subsidiary company called WestVac Biopharma(Guangzhou) has constructed the vector for the Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), and produced trivalent recombinant protein vaccines of high purity and high quality for human use. The subunit vaccine antigen is precisely designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB and BA.5, and can self-assemble into stable trimeric protein particles. Studies have shown that the vaccine induced high titers of neutralizing antibodies against multiple subvariants, including Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, indicating that it is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants at home and abroad[1].

    About WestVac Biopharma

    WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company integrating vaccine R&D, production and sales system with an annual production capacity of 1.1 billion doses of vaccine., WestVac Biopharma has been selected successfully on the list of unicorn companies from 2021 to 2023. In December 2022, Coviccine® has been approved by the national authority for emergency use, and is on the vaccine procurement list in the bidding process in over 20 provinces in China.

    Reference:

    [1] https://pubmed.ncbi.nlm.nih.gov/37125241/

    Photo – https://mma.prnewswire.com/media/2080167/1.jpg
    Photo –

    Cision View original content:https://www.prnewswire.co.uk/news-releases/the-first-of-its-kind-in-the-world-the-recombinant-multivalent-covid-19-protein-vaccine-against-xbb-variants-by-westvac-biopharmawest-china-medical-center-sichuan-university-has-been-approved-for-clinical-trials-by-the-national-301828570.html

    Related Posts

    TÜV SÜD opens its International Technology & Innovation Campus in the Guangdong-Hong Kong-Macao Greater Bay Area

    November 20, 2026

    Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026

    November 20, 2026

    UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan

    November 19, 2026

    Lianlian DigiTech Launches LianLian XWorker, an AI Workforce Platform for Global Commerce

    November 19, 2026

    Getac Expands OS Choice for Highly Regulated Industries with Red Hat® Enterprise Linux® Certification Across Three Fully Rugged Devices

    November 19, 2026

    Sinopec Hosts Side Event at COP31’s CHINA PAVILION, Releases Energy and Green Fuel Outlooks

    November 19, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Regional budget carriers are aggressively capturing market share by deepening direct commercial connectivity across the Middle East. Highlighting this corporate expansion strategy, airline representatives confirm that Air Arabia Egypt launches Cairo to Al Ain flights starting December 2, 2026. The

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026
    © 2026 Quds Sun | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.